-
Orexigen Therapeutics Founder Resigns From Board
Obesity specialist Orexigen Therapeutics Inc. has announced that its co-founder and former chair, Eckard Weber, has stepped down from the board of directors. Weber, who co-founded the company with Michael Cowley in 2002, was chair from 2002 until earlier this year, and also served as interim president and CEO between November 2008 and March 2009. Weber is also a partner at Domain Associates, LLC., a venture capital firm which owns approximately 11.3 million shares of Orexigen common stock.
More from Executives On The Move
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.
Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.
Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.
More from Leadership
• By
Series B cash will be used to advance its Stargardt disease gene therapy.
• By
Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.